LONGEVA.

DSIP: adverse events and evidence limits

The inspected abstract describes intravenous DSIP in 16 chronic-insomnia patients over five laboratory nights. [1]

It reports sleep outcomes rather than adverse-event counts; clinical incidence cannot be derived from this abstract. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Adverse events16 patients with chronic insomnia, intravenous, five laboratory nightsThe abstract reports sleep outcomes rather than adverse-event counts; clinical incidence cannot be derived from it[1]

References

  1. F Bes et al. (1992). Effects of Delta Sleep-Inducing Peptide on Sleep of Chronic Insomniac Patients. 10.1159/000118919.